



Stockholm, 2020-02-11

## PRESS RELEASE

### **QuiaPEG presents positive pre-clinical results for QPG-1029**

**QuiaPEG Pharmaceuticals Holding AB (publ) ("QuiaPEG"), which develops versions of clinically validated or already approved drugs, today presented positive results from a preclinical study in the research project QPG-1029 (pegylated liraglutide), for the treatment of type 2 diabetes and overweight. The study evaluated the pharmacokinetic properties of QPG-1029 after intravenous and subcutaneous administration in rats.**

The results of the preclinical study with QPG-1029 show for the first time that QPG-1029 can be absorbed into the bloodstream after subcutaneous injection (under the skin) and the drug liraglutide is released into blood plasma after both intravenous (in the blood) and subcutaneous administration. The plasma half-life of liraglutide was significantly prolonged after the administration of QPG-1029 compared to the direct administration of liraglutide, which is desirable and in line with expectations.

*"With these positive results as a basis, it will be very interesting to evaluate the effect of QPG-1029 on appetite and weight in our proof-of-concept study," says Cecilia Kemi, Chief Operating Officer.*

The results validate the company's technological platform Uni-Qleaver®. The pharmacological properties of QPG-1029 are consistent with the goal of being able to develop a treatment for type 2 diabetes and obesity with weekly dose administration, instead of daily, which is the case for liraglutide. This saves patients the inconvenience of daily injections, while QPG-1029 treatment is expected to give even levels of liraglutide in blood plasma, which can lead to fewer and milder side effects while improving clinical efficacy.

The results mean that QuiaPEG will continue the QPG-1029 development program. After evaluation of the treatment effect in the proof-of-concept study, pharmacokinetic studies with repeated dosing as well as toxicology and safety studies will be performed before the clinical program can start.

Liraglutide is an approved drug with annual sales of about \$ 4 billion and the basic patent expires in 2022. Liraglutide was developed by Novo Nordisk and sold under the Victoza and Saxenda brands within the indications type 2 diabetes and obesity.

More than half a billion individuals globally are affected by diabetes, most of whom have type 2 diabetes. The market for diabetes drugs was estimated at \$ 31 billion in 2015 (GlobalData) and annual growth is estimated to be around 6.5% by 2025.

**For more information, please contact:**

Marcus Bosson

Tel: 070-6931253

E-mail: marcus.bosson@quiapeg.com

*This information is such that QuiaPEG Pharmaceuticals Holding AB (publ) is required to disclose under the EU Market Abuse Regulation. The information was provided, through the above named contact person, for publication on February 11, 2020.*

**About QuiaPEG**

QuiaPEG Pharmaceuticals Holding AB (publ) is a drug development company based on a patented so-called drug delivery platform, Uni-Qleaver®. The company develops improved and patentable forms of drugs under development or which have already been approved by pharmaceutical authorities. These refined and better forms of pharmaceuticals are based on the company's unique and patented technology platform. The company is listed on Spotlight (ticker: QUIA).